CN103031365B - ATM gene mutation detection specific primer and liquid chip - Google Patents
ATM gene mutation detection specific primer and liquid chip Download PDFInfo
- Publication number
- CN103031365B CN103031365B CN201110299855.5A CN201110299855A CN103031365B CN 103031365 B CN103031365 B CN 103031365B CN 201110299855 A CN201110299855 A CN 201110299855A CN 103031365 B CN103031365 B CN 103031365B
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- site
- tag
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 46
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 26
- 101150065175 Atm gene Proteins 0.000 title claims abstract description 25
- 239000007788 liquid Substances 0.000 title abstract description 6
- 241000183024 Populus tremula Species 0.000 claims abstract description 38
- 102200058567 rs587782292 Human genes 0.000 claims abstract description 23
- 102200057780 rs1800056 Human genes 0.000 claims abstract description 19
- 102200058498 rs587781894 Human genes 0.000 claims abstract description 17
- 102200058365 rs587782310 Human genes 0.000 claims abstract description 17
- 102220001197 rs121434219 Human genes 0.000 claims abstract description 15
- 239000007791 liquid phase Substances 0.000 claims description 27
- 230000000869 mutational effect Effects 0.000 claims description 20
- 102000000872 ATM Human genes 0.000 claims description 13
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 abstract description 7
- 230000003321 amplification Effects 0.000 abstract description 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000004005 microsphere Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 18
- 238000013461 design Methods 0.000 description 17
- 230000008859 change Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an ATM gene mutation detection specific primer and a liquid chip. The liquid chip mainly comprises ASPE primers consisting of tag sequences at a 5' end and specific primer sequences aiming at target gene mutation sites at a 3' end, microspheres coated with anti-tag sequences and an amplification primer, wherein the specific primer sequences are as follows: SEQ ID NO.13 and SEQ ID NO.14 which aim at a T2572C site, SEQ ID NO.15 and SEQ ID NO.16 which aim at an A7325C site, SEQ ID NO.17 and SEQ ID NO.18 which aim at a G7328A site, SEQ ID NO.19 and SEQ ID NO.20 which aim at a C9022T site, SEQ ID NO.21 and SEQ ID NO.22 which aim at a G9023A site, and/or SEQ ID NO.23 and SEQ ID NO.24 which aim at a C9139T site. The detection liquid chip provided by the invention has the advantages that the matching rate between the detection result and a sequencing method is up to 100%, and the wild-type and mutant parallel detection of multiple mutant sites can be realized.
Description
Technical field
The invention belongs to biology field, relate to medical science and biotechnology, concrete a kind of ATM detection in Gene Mutation Auele Specific Primer and the liquid-phase chip of relating to.
Background technology
Louis-Bar syndrome mutator gene (ataxia-telangiectasia mutated, ATM) be the Disease-causing gene that causes louis-Bar syndrome to occur, ATM gene is an important signal pick-off, in DNA damage repair process, ATM detects the DNA of damage as recognition factor, thereby and passes through the two chain breaks of target protein phosphorylation DNA plerosis.
ATM gene is positioned at karyomit(e) 11q22.3, and length is 150kb, has 66 exons, and the 4th exon is first coding exon.ATM albumen is the macromole nuclear phosphoprotein of a kind of phosphorylation of ATM genes encoding, contains 3056 amino acid.There are some researches show, the generation of ATM transgenation and tumour is closely related.
At present, the method that ATM transgenation is carried out to determination and analysis seldom, mainly contains direct sequencing and PCR-RFLP analytical method, and wherein the most frequently used method has PCR-RFLP analytical method.PCR-RFLP method is the change of the restriction enzyme enzyme recognition site that causes based on transgenation, as lost or generation novel site in site, by a certain specific fragment of pcr amplification, use again digestion with restriction enzyme amplified production, the size of electrophoresis observation fragment, the transgenation that this method changes for detection of restriction enzyme site, can directly judge genotype, but this method can not be for producing the detection in Gene Mutation of new restriction enzyme site.Again, above these methods all exist the limitation that detects flux, can only detect a kind of mutation type at every turn, can not meet the needs of practical application.
Summary of the invention
One of object of the present invention is to provide ATM gene mutation detection liquid-phase chip, and this liquid-phase chip can be used for separately or wild-type and the saltant type of parallel detection ATM gene six kinds of common genotype T2572C, A7325C, G7328A, C9022T, G9023A and C9139T.
The technical scheme that realizes above-mentioned purpose is as follows:
An ATM gene mutation detection liquid-phase chip, includes:
(A). the wild-type designing respectively for the different mutational sites of ATM gene and the ASPE primer of saltant type: every kind of ASPE primer holds the specific primer sequence for goal gene mutational site to form by the tag sequence and 3 ' of 5 ' end, and described specific primer sequence is: for SEQ ID NO.13 and the SEQ ID NO.14 in T2572C site; SEQ ID NO.15 and SEQ ID NO.16 for A7325C site; SEQ ID NO.17 and SEQ ID NO.18 for G7328A site; SEQ ID NO.19 and SEQ ID NO.20 for C9022T site; SEQ ID NO.21 and SEQ ID NO.22 for G9023A site; And/or for SEQ ID NO.23 and the SEQ ID NO.24 in C9139T site; Described tag sequence is selected from SEQ ID NO.1～SEQ ID NO.12;
(B). there is anti-tag sequence microballoon coated, that there is different colours coding, in the middle of described anti-tag sequence is connected with microballoon, be also provided with spacerarm sequence; Described anti-tag sequence is selected from SEQ ID NO.25～SEQ ID NO.36, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). for amplifying the primer that needs target sequence detection, that there is corresponding mutational site.
Preferably, described amplimer is: for SEQ ID NO.37 and the SEQ ID NO.38 in T2572C site; SEQ ID NO.39 and SEQ ID NO.40 for A7325C, G7328A site; And/or for SEQ ID NO.41 and the SEQ ID NO.42 in C9022T, G9023A, C9139T site.
Preferably, described ASPE primer is: for the sequence being comprised of SEQ ID NO.1 and SEQ ID NO.13 in T2572C site and the sequence being comprised of SEQ ID NO.2 and SEQ ID NO.14; For the sequence being formed by SEQ ID NO.3 and SEQ ID NO.15 in A7325C site and the sequence being formed by SEQ ID NO.4 and SEQ ID NO.16; For the sequence being formed by SEQ ID NO.5 and SEQ ID NO.17 in G7328A site and the sequence being formed by SEQ ID NO.6 and SEQ ID NO.18; For the sequence being formed by SEQ ID NO.7 and SEQ ID NO.19 in C9022T site and the sequence being formed by SEQ ID NO.8 and SEQID NO.20; For the sequence being formed by SEQ ID NO.9 and SEQ ID NO.21 in G9023A site and the sequence being formed by SEQ ID NO.10 and SEQ ID NO.22; And/or for the sequence being formed by SEQ ID NO.11 and SEQID NO.23 in C9139T site and the sequence being formed by SEQ ID NO.12 and SEQ ID NO.24.
Another object of the present invention is to provide the Auele Specific Primer for ATM detection in Gene Mutation.
The technical scheme that realizes above-mentioned purpose is as follows:
For the Auele Specific Primer of ATM detection in Gene Mutation liquid, it is: for SEQ ID NO.13 and the SEQ ID NO.14 in T2572C site; SEQ ID NO.15 and SEQ ID NO.16 for A7325C site; SEQ ID NO.17 and SEQ ID NO.18 for G7328A site; SEQ ID NO.19 and SEQ ID NO.20 for C9022T site; SEQ ID NO.21 and SEQ ID NO.22 for G9023A site; And/or for SEQ ID NO.23 and the SEQ ID NO.24 in C9139T site.
Major advantage of the present invention is:
1. the identical rate of detection method provided by the present invention and sequencing is up to 100%.And detect the needed time well below conventional sequencing technologies, realistic especially application needs.Prepared ATM gene mutation detection liquid-phase chip has extraordinary signal-noise ratio, and between designed probe and anti-tag sequence, substantially there is not cross reaction, choosing and tag sequence label and the specifically combination of ASPE primer of tag sequence label, anti-tag sequence label, can avoid cross reaction, realize the parallel detection in a plurality of mutational sites.
2. the present invention, by the design experiences of the long-term accumulation of contriver and a large amount of experimental implementation, has chosen optimum combination from numerous Auele Specific Primers.The ASPE primer specificity primer of the present invention design can the sensitive mutational site of identifying specifically target detect, accurately distinguishes the genotype of various types; In same reaction system, between different Auele Specific Primers, substantially there is not cross reaction between Auele Specific Primer and the pcr amplification product of non-target detect, detection specificity is good, and cross reacting rate is lower than 3%; Except detecting Single locus sudden change situation, also the sudden change situation in a plurality of mutational sites of parallel detection simultaneously, detects effect consistent.
3. detection method step of the present invention is simple, 6 kinds of mutational sites are detected and can be completed the amplification of 3 target sequences that contain mutational site by a step PCR, the many uncertain factors that exist in the complex operations processes such as repeated multiple times PCR have been avoided, thereby can greatly improve Detection accuracy, embodied accurate while qualitative and quantitative analysis feature.
4. not only to have overcome traditional solid phase chip susceptibility not high in the present invention, and the poor defect of repeatability of detected result is improved existing liquid-phase chip technology simultaneously, makes prepared microballoon can be applicable to different test items, has very strong expansion.The fluorescent signal value detecting improves greatly, thereby the sensitivity detecting is further enhanced, and signal to noise ratio strengthens, and detected result more accurately and reliably.
Embodiment
Embodiment 1ATM gene mutation detection liquid-phase chip, mainly includes:
One, ASPE primer
Wild-type and saltant type for ATM gene six kinds of common genotype T2572C, A7325C, G7328A, C9022T, G9023A and C9139T, design respectively specific primer sequence.ASPE primer is comprised of " tag sequence+specific primer sequence ".ASPE primer sequence is as shown in the table:
The ASPE primer sequence (tag sequence+specific primer sequence) of table 1ATM gene
Every ASPE primer comprises two parts, and 5 ' end is the specificity tag sequence for anti-tag sequence on corresponding microballoon, and 3 ' end is saltant type or the special primer fragment (as shown in Table 1 above) of wild-type.All ASPE primers are synthesized by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
Two, the coated microballoon of anti-tag sequence
According to designed ASPE Auele Specific Primer fragment, select tag sequence, reduce to greatest extent between the anti-tag sequence of each microballoon and secondary structure that tag and ASPE Auele Specific Primer fragment may form, on 12 kinds of microballoons numberings of selection and microballoon, corresponding anti-tag sequence is as shown in table 2:
Corresponding anti-tag sequence on table 2 microballoon numbering and microballoon
12 kinds of microballoons selecting, purchased from U.S. Luminex company, are coated in anti-tag sequence on microballoon.Between anti-tag sequence and microballoon, be connected with the spacerarm sequence of 5-10 T, before each anti-tag sequence, add the spacerarm sequence of the preceding paragraph 5-10 T, anti-tag sequence is synthesized by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.By synthetic anti-tag sequence sterilizing ddH
2o is made into the stock solution of 100nmol/ml.Described spacerarm is for for by anti-tag and microsphere surface is spaced apart or anti-tag is placed in to the sequence of hydrophilic environments.By the spacerarm sequence of suitable length is set between anti-tag sequence and microballoon, can reduce sterically hinderedly, improve the efficiency of hybridization and the specificity of hybridization.Common spacerarm sequence comprises poly dT, i.e. poly (dT), and oligomerization four polyoxyethylene glycol and (CH2) n spacerarm (n >=3), as (CH2) 12, (CH2) 18 etc.In addition, if exist poly (dA) to disturb, can also use poly (TTG) as spacerarm.Spacerarm of the present invention is preferably 5-10 T, and the coated process of microballoon is as follows:
Get respectively 5 * 10
6the carboxylated microballoon of individual above-mentioned numbering (purchased from Luminex company) is suspended in the MES solution of 50ul 0.1mol/L (pH4.5), adds the synthetic anti-tag molecule (100nmol/ml) of 10ul.EDC (N-(3-Dimethylaminopropyl-N-ethylcarbodiimide) (purchased from the Pierce Chemical company) working fluid of preparation 10ng/ml.Toward the EDC working fluid that adds 2.5ul in microballoon suspension, constant-temperature incubation 30 minutes, then add the EDC working fluid of 2.5ul, then constant-temperature incubation 30 minutes.After reaction finishes, the Tween-20 with 0.02% washs once, then washs once with 0.1% SDS liquid.The Tris-EDTA solution [10mmol/L Tris (pH8.0)] that the microballoon that is coated with anti-tag sequence after washing is resuspended in to 100ul, in 1mmol/LEDTA, 2-8 ℃ keeps in Dark Place.
Three, amplify the primer of the target sequence that contains mutational site
For ATM gene six kinds of common genotype T2572C, A7325C, G7328A, C9022T, G9023A and C9139T, design of amplification primers, to (in Table 3), amplifies 3 target sequences that contain 6 mutational sites.
Table 3 amplifies the primer of the target sequence with mutational site
All primers are synthesized by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
The detection of ATM gene mutation detection liquid-phase chip described in embodiment 2 utilization embodiment 1 to sample
The formula of described various solution is as follows:
MES damping fluid (pH5.0) formula (250ml) of 50mM:
2 * Tm hybridization buffer
| Reagent | Source | Final concentration | The consumption of every 250ml |
| 1MTris-HCl， | SigmaT3038 | 0.2M | 50ml |
| pH8.0 | |||
| 5MNaCl | Sigma S5150 | 0.4M | 20ml |
| Triton X-100 | Sigma T8787 | 0.16％ | 0.4ml |
After filtration, be stored in 4 ℃.
ExoSAP-IT test kit is purchased from U.S. USB company.
Biotin labeled dCTP is purchased from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.
One, the DNA extraction of sample:
Methods involving with reference to < < molecular cloning > > about DNA extraction, obtains DNA to be detected.
Two, the pcr amplification of testing sample
Design 3 pairs of primers, multiplex PCR one step amplifies 3 target sequences that contain respectively ATM gene six kinds of common genotype T2572C, A7325C, G7328A, C9022T, G9023A and C9139T, product size is respectively 280bp, 426bp and 407bp, and primer sequence (SEQ ID NO.37-42) is shown in shown in above-mentioned table 3.
First prepare multiple PCR primer working fluid: respectively get respectively the primer stock solution 100ul of SEQ ID NO.37-42 in 1.5ml Eppendorf tube, mix and be multiple PCR primer working fluid.Multi-PRC reaction system is as follows:
Pcr amplification program is: 95 ℃ of 3min; 94 ℃ of 30s, 56 ℃ of 30s, 72 ℃ of 40s, 30 circulations; 72 ℃ of 10min; 4 ℃ save backup.
Three, the enzyme of PCR product is cut processing
1. get the reacted product of 7.5ul PCR, add 1ul 10 * SAP damping fluid, 1ul SAP enzyme and 0.5ul Exo-I enzyme;
Hatch 15min for 2.37 ℃, hatch 15min for 80 ℃, the enzyme that deactivation is unnecessary.The product that enzyme is cut after processing is directly used in follow-up ASPE primer extension reaction.
Four, site-specific primer extension reaction (ASPE)
Utilize the ASPE primer of above-mentioned design to carry out primer extension reaction, in reaction process, mix biotin labeled dCTP, thereby make a plurality of biotin labeling on reacted product band.
First the ASPE primer working fluid that preparation mixes: get respectively the corresponding wild-type of gene to be detected and saltant type ASPE primer stock solution 10ul in 1.5ml Eppendorf tube, add 10mmol/L Tris Buffer to mend to 200ul, mix and be ASPE mix primer working fluid.The system of ASPE reaction is as follows:
Response procedures is: 96 ℃ of 2min; 94 ℃ of 30s, 54 ℃ of 1min, 72 ℃ of 2min, 30 circulations; 4 ℃ save backup.
Five, hybridization
According to design ASPE primer, the corresponding 12 kinds of coated microballoons of every group selection (as described in Example 1), every kind of microballoon concentration is 2.5 * 10
5individual/ml;
2. get respectively the microballoon of every kind of numbering of 1ul in the Eppendorf tube of 1.5ml;
3. microballoon is in >=centrifugal the 1-2min of 10000g;
4. supernatant discarded, microballoon is resuspended in 2 * Tm hybridization buffer of 100ul, and vortex mixes;
5. get the above-mentioned microballoon suspension of 25ul in the 96 corresponding holes of hole filter plate, control wells adds the ddH of 25ul
2o;
6. get the ASPE reaction solution of 5-25ul in corresponding hole, use ddH
2o complements to 50ul;
7. with masking foil, encase 96 orifice plates with lucifuge, 95 ℃ of 60s, 37 ℃ of 15min are hatched hybridization;
8. the microballoon after hybridization is in >=centrifugal the 2-5min of 3000g;
9. remove supernatant, microballoon is resuspended in 1 * Tm hybridization buffer of 75ul;
10. microballoon is in >=centrifugal the 2-5min of 3000g;
11. are resuspended in microballoon in 1 * Tm hybridization buffer of 75ul, and adding 15ul concentration is the SA-PE (SA-PE) of 10ug/ml;
Hatch 15min for 12.37 ℃, on Luminex instrument, detect.
Six, result detects and data analysis
Reaction after product detects by Luminex serial analysis instrument.The saltant type fluorescent value (MFI) of take is greater than 100 as cut-off value, when the MFI value of saltant type detection is greater than 100, judges that this sample exists this mutation type, otherwise judges that this sample is as corresponding wild-type.
Use present method to detect the ATM transgenation of great amount of samples, with sequencing, detect with liquid-phase chip result and compare, calculate the identical rate of method detected result provided by the present invention.Present method detects 20 increments ATM genotype detection result and the sequencing result rate of coincideing originally and reaches 100%.Visible ATM gene mutation detection liquid-phase chip provided by the present invention can detect the mutation type of ATM gene exactly, and result is reliable and stable.
One of table 4 pattern detection result (MFI)
Two of table 5 pattern detection result (MFI)
Table 6 sample ATM gene mutation type analytical results
| Catalogue number(Cat.No.) | Liquid-phase chip detected result | Sequencing result |
| 1 | G9023A sudden change | G9023A sudden change |
| 2 | Wild-type | Wild-type |
| 3 | A7325C sudden change | A7325C sudden change |
| 4 | Wild-type | Wild-type |
| 5 | Wild-type | Wild-type |
| 6 | Wild-type | Wild-type |
| 7 | Wild-type | Wild-type |
| 8 | T2572C sudden change | T2572C sudden change |
| 9 | Wild-type | Wild-type |
| 10 | Wild-type | Wild-type |
| 11 | C9022T sudden change | C9022T sudden change |
| 12 | Wild-type | Wild-type |
| 13 | Wild-type | Wild-type |
| 14 | Wild-type | Wild-type |
| 15 | Wild-type | Wild-type |
| 16 | C9022T sudden change | C9022T sudden change |
| 17 | Wild-type | Wild-type |
| 18 | Wild-type | Wild-type |
| 19 | Wild-type | Wild-type |
| 20 | Wild-type | Wild-type |
The detection of the liquid-phase chip of the ASPE primer that embodiment 3 is different to ATM gene mutation site
One, the design that prepared by liquid-phase chip (selection of tag sequence and Anti-tag sequence)
Take ATM gene T2572C and G7328A site mutation, to detect liquid-phase chip be example, respectively for the wild-type of T2572C and G7328A and the specific primer sequence of saltant type design ASPE primer 3 ' end, the tag sequence of ASPE primer 5 ' end is selected from SEQ ID NO.1-SEQ ID NO.12, accordingly, the anti-tag sequence with corresponding tag sequence complementary pairing being coated on microballoon is selected from SEQ ID NO.25-SEQ ID NO.36.Specific design is as shown in following table (table 7).Synthetic, the anti-tag sequence of ASPE primer are coated with microballoon, amplimer, detection method etc. as described in embodiment 1 and embodiment 2.
Design prepared by table 7 liquid-phase chip
Two, sample detection
The liquid-phase chip that adopts above-mentioned design to prepare, detects sample 21-40 by testing process described in embodiment 2 and method, and detected result is as follows:
Table 8 pattern detection result and gene mutation analysis
Table 9 pattern detection result and gene mutation analysis
From experimental result, ASPE primer uses different Tag sequences, and its result is still reliable and stable, but ASPE primer is while selecting in embodiment 1 collocation of tag sequence and specific primer sequence, effect better (signal to noise ratio is better), referring to the present embodiment test group 1 and test group 5.Other different tag sequences and specific primer sequence collocation, with coming to the same thing of embodiment 2 and the present embodiment, concrete data are omitted.
Other is for the liquid-phase chip in different mutational sites, and ASPE primer uses different Tag sequences, and its result is still reliable and stable, and while selecting in embodiment 1 collocation of tag sequence and specific primer sequence, effect is better, and concrete data are omitted.
The selection of embodiment 4ATM detection in Gene Mutation specific primer sequence
One, the design that prepared by liquid-phase chip (selection of wild-type and saltant type specific primer sequence)
Take the mutational site of ATM Gene A 7325C and C9022T, to detect liquid-phase chip be example, the complementary sequence forward or backwards of this place, mutational site target sequence of take is template, respectively for the wild-type of A7325C and C9022T and the specific primer sequence of saltant type design ASPE primer 3 ' end, comprise preferred specific primer sequence and 2 alternative specific primer sequences in the embodiment of the present invention 1, as shown in table 10.Wherein,
interior base is mutational site.
Table 10 specific primer sequence
Take the mutational site of ATM Gene A 7325C and C9022T, to detect liquid-phase chip be example, for A7325C and C9022T, select different specific primer sequences, the tag sequence of ASPE primer 5 ' end is fixed as the best effect sequence in embodiment 1, and select the anti-tag sequence of answering in contrast, specific design is as shown in following table (table 11).Synthetic, the anti-tag sequence of ASPE primer are coated with microballoon, amplimer, detection method etc. as described in embodiment 1 and embodiment 2.
Two of design prepared by table 11 liquid-phase chip
Two, sample detection
The liquid-phase chip that adopts above-mentioned design to prepare, detects sample 41-60 by testing process described in embodiment 2 and method, and detected result is as follows:
Table 12 pattern detection result and gene mutation analysis
Table 13 pattern detection result and gene mutation analysis
From the present embodiment, when ASPE primer is selected in embodiment 1 collocation of specific primer sequence and tag sequence, effect better (signal to noise ratio is better), referring to the present embodiment test group 7 and test group 10.Other derives from different specific primer sequences and the collocation of tag sequence of the complementary sequence forward or backwards of place, target detect site sequence, with coming to the same thing of embodiment 2 and the present embodiment, be still that the specific primer sequence described in embodiment 1 is better from different tag sequence arranging effects, concrete data are omitted.
Other multiple specific primer sequence for different mutational sites and the collocation of tag sequence, with coming to the same thing of embodiment 2 and the present embodiment, the selected Auele Specific Primer of embodiment 1, has better signal to noise ratio, detect effect also better, concrete data are omitted.
Be more than for the illustrating of possible embodiments of the present invention, but this embodiment is not in order to limit the scope of the claims of the present invention, allly do not depart from the equivalence that skill spirit of the present invention does and implement or change, all should be contained in the scope of the claims of the present invention.
Claims (5)
1. an ATM gene mutation detection liquid-phase chip, is characterized in that, includes:
(A). the wild-type designing respectively for the different mutational sites of ATM gene and the ASPE primer of saltant type: every kind of ASPE primer holds the specific primer sequence for goal gene mutational site to form by the tag sequence and 3 ' of 5 ' end, and described specific primer sequence is: for SEQ ID NO.13 and the SEQ ID NO.14 in T2572C site; And be selected from SEQ ID NO.15 and the SEQ ID NO.16 for A7325C site; SEQ ID NO.17 and SEQ ID NO.18 for G7328A site; SEQ ID NO.19 and SEQ ID NO.20 for C9022T site; SEQ ID NO.21 and SEQ ID NO.22 for G9023A site; With in SEQ ID NO.23 for C9139T site and SEQ ID NO.24 at least one group; Described tag sequence is selected from SEQ ID NO.1～SEQ ID NO.12;
(B). there is anti-tag sequence microballoon coated, that there is different colours coding, in the middle of described anti-tag sequence is connected with microballoon, be also provided with spacerarm sequence; Described anti-tag sequence is selected from SEQ ID NO.25～SEQ ID NO.36, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). for amplifying the primer that needs target sequence detection, that have corresponding mutational site, described amplimer is: for SEQ ID NO.37 and the SEQ ID NO.38 in T2572C site; And be selected from SEQ ID NO.39 and the SEQ ID NO.40 for A7325C, G7328A site; With in SEQ ID NO.41 for C9022T, G9023A, C9139T site and SEQ ID NO.42 at least one group.
2. ATM gene mutation detection liquid-phase chip according to claim 1, it is characterized in that, described ASPE primer is: for the sequence being comprised of SEQ ID NO.1 and SEQ ID NO.13 in T2572C site and the sequence being comprised of SEQ ID NO.2 and SEQ ID NO.14; And be selected from for the sequence being formed by SEQ ID NO.3 and SEQ ID NO.15 in A7325C site and the sequence being formed by SEQ ID NO.4 and SEQ ID NO.16; For the sequence being formed by SEQ ID NO.5 and SEQ ID NO.17 in G7328A site and the sequence being formed by SEQ ID NO.6 and SEQ ID NO.18; For the sequence being formed by SEQ ID NO.7 and SEQ ID NO.19 in C9022T site and the sequence being formed by SEQ ID NO.8 and SEQ ID NO.20; For the sequence being formed by SEQ ID NO.9 and SEQ ID NO.21 in G9023A site and the sequence being formed by SEQ ID NO.10 and SEQ ID NO.22; With in the sequence being formed by SEQ ID NO.11 and SEQ ID NO.23 for C9139T site and the sequence that formed by SEQ ID NO.12 and SEQ ID NO.24 at least one group.
3. ATM gene mutation detection liquid-phase chip according to claim 1, is characterized in that,
(A) described ASPE primer is: for the sequence being comprised of SEQ ID NO.1 and SEQ ID NO.13 in T2572C site and the sequence being comprised of SEQ ID NO.2 and SEQ ID NO.14; For the sequence being formed by SEQ ID NO.3 and SEQ ID NO.15 in A7325C site and the sequence being formed by SEQ ID NO.4 and SEQ ID NO.16; For the sequence being formed by SEQ ID NO.5 and SEQ ID NO.17 in G7328A site and the sequence being formed by SEQ ID NO.6 and SEQ ID NO.18; For the sequence being formed by SEQ ID NO.7 and SEQ ID NO.19 in C9022T site and the sequence being formed by SEQ ID NO.8 and SEQ ID NO.20; For the sequence being formed by SEQ ID NO.9 and SEQ ID NO.21 in G9023A site and the sequence being formed by SEQ ID NO.10 and SEQ ID NO.22; With the sequence being formed by SEQ ID NO.11 and SEQ ID NO.23 for C9139T site and the sequence being formed by SEQ ID NO.12 and SEQ ID NO.24;
(B) there is anti-tag sequence microballoon coated, that there is different colours coding, in the middle of described anti-tag sequence is connected with microballoon, be also provided with spacerarm sequence; Described anti-tag sequence is selected from SEQ ID NO.25～SEQ ID NO.36, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C) described amplimer is: for SEQ ID NO.37 and the SEQ ID NO.38 in T2572C site; SEQ ID NO.39 and SEQ ID NO.40 for A7325C, G7328A site; With SEQ ID NO.41 and the SEQ ID NO.42 for C9022T, G9023A, C9139T site.
4. according to the ATM gene mutation detection liquid-phase chip described in claim 1-3 any one, it is characterized in that, described spacerarm is 5-10 T.
5. for the Auele Specific Primer of ATM detection in Gene Mutation, it is characterized in that, described specific primer sequence is: for SEQ ID NO.13 and the SEQ ID NO.14 in T2572C site; And be selected from SEQ ID NO.15 and the SEQ ID NO.16 for A7325C site; SEQ ID NO.17 and SEQ ID NO.18 for G7328A site; SEQ ID NO.19 and SEQ ID NO.20 for C9022T site; SEQ ID NO.21 and SEQ ID NO.22 for G9023A site; With in SEQ ID NO.23 for C9139T site and SEQ ID NO.24 at least one group.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110299855.5A CN103031365B (en) | 2011-09-30 | 2011-09-30 | ATM gene mutation detection specific primer and liquid chip |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110299855.5A CN103031365B (en) | 2011-09-30 | 2011-09-30 | ATM gene mutation detection specific primer and liquid chip |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103031365A CN103031365A (en) | 2013-04-10 |
| CN103031365B true CN103031365B (en) | 2014-11-26 |
Family
ID=48018764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110299855.5A Expired - Fee Related CN103031365B (en) | 2011-09-30 | 2011-09-30 | ATM gene mutation detection specific primer and liquid chip |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103031365B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104178487B (en) * | 2013-05-20 | 2017-09-19 | 中南大学湘雅医院 | ATM gene mutant and application thereof |
| US10619208B2 (en) * | 2015-01-19 | 2020-04-14 | Erydel S.P.A. | Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101984070A (en) * | 2010-09-21 | 2011-03-09 | 广州益善生物技术有限公司 | c-KIT gene mutation detection liquid-phase chip |
-
2011
- 2011-09-30 CN CN201110299855.5A patent/CN103031365B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101984070A (en) * | 2010-09-21 | 2011-03-09 | 广州益善生物技术有限公司 | c-KIT gene mutation detection liquid-phase chip |
Non-Patent Citations (4)
| Title |
|---|
| ATM Haplotypes and Cellular Response to DNA Damage: Association with Breast Cancer Risk and Clinical Radiosensitivity;Sandra et al;《CANCER RESEARCH》;20031215;摘要，表1-2 * |
| ATM 基因与肿瘤的发生;任军等;《肿瘤防治杂志》;20041231;第11卷(第5期);535-538 * |
| Sandra et al.ATM Haplotypes and Cellular Response to DNA Damage: Association with Breast Cancer Risk and Clinical Radiosensitivity.《CANCER RESEARCH》.2003,摘要，表1-2. * |
| 任军等.ATM 基因与肿瘤的发生.《肿瘤防治杂志》.2004,第11卷(第5期),535-538. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103031365A (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102994619B (en) | NRAS gene mutation detection specificity primer and liquid chip thereof | |
| CN102994621B (en) | PTPN11 gene mutation detection specificity primer and liquid chip thereof | |
| CN103031365B (en) | ATM gene mutation detection specific primer and liquid chip | |
| CN103031370B (en) | RB1 gene mutation detection specific primer and liquid chip | |
| CN103031369B (en) | CDKN2A gene mutation detection specific primer and liquid chip | |
| CN102912002B (en) | ABCB2 gene polymorphism detection specific primers and liquid chip | |
| CN103031367A (en) | VHL (Von Hippel Lindau) genetic mutation detection specific primer and liquid phase chip | |
| CN102191336B (en) | MYC gene single nucleotide polymorphism (SNP) detection specific primer and liquid-phase chip | |
| CN103031368B (en) | FGFR1 gene mutation detection specific primer and liquid chip | |
| CN103374607B (en) | ABCC (ATP (adenosine triphosphate)-binding cassette, sub-family C)1 gene mutation detection specific primers and liquid chip | |
| CN103031364B (en) | FGFR3 gene mutation detection specific primer and liquid chip | |
| CN103031371B (en) | CDH1 gene mutation detection specific primer and liquid chip | |
| CN102952866B (en) | Specific primer and liquid chip for detecting polymorphism of DPYD (dihydropyrimidine dehydrogenase) gene | |
| CN102994625B (en) | PIK3R1 gene mutation detection specificity primer and liquid chip thereof | |
| CN103031366B (en) | FGFR2 gene mutation detection specific primer and liquid chip | |
| CN102994616B (en) | MEK1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102952874B (en) | Specific primer and liquid chip for detecting polymorphism of SLC22A1 gene | |
| CN102952867B (en) | Specific primer and liquid chip for detecting polymorphism of SLC22A6 gene | |
| CN102994623B (en) | STK11 gene mutation detection specificity primer and liquid chip thereof | |
| CN102952868B (en) | Specific primer and liquid chip for detecting polymorphism of SLC15A2 gene | |
| CN102952872B (en) | Specific primer and liquid chip for detecting polymorphism of SLCO1B3 gene | |
| CN102888444B (en) | Factor II and Factor V genetic polymorphism detection specific primer and liquid-phase chip | |
| CN102191335B (en) | Specific primer and liquid-phase chip for SNP (single nucleotide polymorphism) detection of PIGU (phosphatidylinositol glycan anchor biosynthesis, class U) genes | |
| CN102952869B (en) | Specific primer and liquid chip for detecting polymorphism of SLCO1B1 gene | |
| CN103374608B (en) | MTRR (5-methyltetrahydrofolate-homocysteine methyltransferase reductase) gene mutation detection specific primers and liquid chip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant after: SUREXAM BIO-TECH Co.,Ltd. Address before: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant before: GUANGZHOU SUREXAM BIO-TECH Co.,Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUANGZHOU YISHAN BIOTECHNOLOGY CO., LTD. TO: SUREXAM BIOTECHNOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141126 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |